Why Is Provention Bio (PRVB) Stock Up 263% Today?
- Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.
- 03/13/2023
|
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
- RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
- 03/13/2023
|
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
- Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.
- 03/13/2023
|
Sanofi to buy Provention Bio in deal worth $2.9 billion
- French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with an equity value of $2.9 billion. The deal will allow Sanofi to add to its portfolio, TZIELD, which was approved in the U.S. last year as the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
- 03/13/2023
|
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
- RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.
- 02/23/2023
|
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
- PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades.
- 02/22/2023
|
2 Beaten-Down Stocks That Might Be too Cheap to Ignore
- There is an argument for hitting the buy button, but it's important to consider the potential risks too.
- 02/22/2023
|
Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?
- Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/13/2023
|
Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)
- Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 02/08/2023
|
Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data
- Received FDA approval of TZIELD for Stage 2 Type 1 Diabetes patients in November of 2022. Potential to increase market potential of TZIELD with ongoing phase 3 PROTECT study, which is being used for stage 3 newly diagnosed T1D patients. Results expected 2nd half of 2023.
- 02/07/2023
|
Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch
- After the FDA's approval of Tzield and with better-than-expected pricing, we are upgrading to a Buy rating. PRVB's pricing and approval bode well for the stock and de-risk owning it; however, we are neutral around the Q1-Q2 sales print due to uncertainty around market access.
- 01/02/2023
|
Why Shares of Provention Bio Went Up 30.3% in November
- The company got approval for its lead type 1 diabetes therapy.
- 12/05/2022
|
Is This Biotech Stock a Buy Following a Landmark Approval?
- You may not want to be too quick to pull the trigger.
- 12/04/2022
|
Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes
- Shares of Provention Bio Inc. PRVB, -1.09% were down 3.9% in trading on Friday morning, the day after the Food and Drug Administration approved the company's treatment that can delay the onset of Type 1 diabetes in some patients. The intravenous therapy, Tzield, can delay the onset of Stage 3 Type 1 diabetes in patients with Stage 2 Type 1 diabetes.
- 11/18/2022
|
Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript
- Provention Bio, Inc. (NASDAQ:PRVB ) Q3 2022 Results Conference Call November 3, 2022 8:00 AM ET Company Participants Heidy King-Jones - Chief Legal Officer Ashleigh Palmer - CEO and Co-Founder Jason Hoitt - Chief Commercial Officer Thierry Chauche - CFO Conference Call Participants Justin Kim - Oppenheimer Chris Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Thomas Smith - SVB Securities Prakhar Agrawal - Cantor Fitzgerald David Hoang - SMBC Operator Good morning.
- 11/03/2022
|
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
- It may be a mixed session for the overall market on Thursday, but not for Provention Biosciences (NASDAQ: PRVB ). That's as PRVB stock is up 25% so far in the session and hitting its highest level since July 2021.
- 11/03/2022
|
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
- Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 26.09% and 13.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
- Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
- 10/07/2022
|
Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?
- Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 10/07/2022
|
2 Stocks Jumping in Thursday's Premarket Trading
- Get an early start on the events of the day.
- 10/06/2022
|
1 Green Flag and 1 Red Flag for Provention Bio
- It could be a make-or-break end of the year for the company.
- 09/22/2022
|
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C.
- 09/06/2022
|
2 Under-the-Radar Biotech Stocks to Buy in 2022
- It's been a wild 12 months for these companies.
- 08/12/2022
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript
- Provention Bio, Inc. (NASDAQ:PRVB ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche - Chief Financial Officer Ashleigh Palmer - Co-Founder, President, Chief Executive Officer Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientific Officer Conference Call Participants Justin Kim - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Prakhar Agrawal - Cantor Fitzgerald Thomas Smith - SVB Securities David Hoang - SMBC Nikko Operator Good morning.
- 08/06/2022
|
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
- Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
- RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022, before the opening of the U.S. financial markets.
- 07/28/2022
|
This Stock Could Soar by Nearly 300%, Says Wall Street
- Are the Street's predictions too optimistic?
- 07/26/2022
|
Provention Bio to Present at the Jefferies Global Healthcare Conference
- RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8 th 2022 at 9:00 am EST in New York City.
- 06/03/2022
|
2 High-Risk, High-Reward Stocks for Contrarian Investors
- Feeling adventurous?
- 05/19/2022
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2022 Results - Earnings Call Transcript
- Provention Bio, Inc. (NASDAQ:PRVB ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ashleigh Palmer – Co-Founder, President, Chief Executive Officer Francisco Leon – Co-Founder & Chief Scientific Officer Thierry Chauche – Chief Financial Officer Jason Hoitt – Chief Commercial Officer Robert Doody – Vice President, Investor Relations Conference Call Participants Gregory Renza – RBC Capital Markets Thomas Smith – SVB Leerink David Hoang – SMBC Nikko Securities America, Inc Operator Good morning. My name is Kate, and I will be your conference Operator today.
- 05/05/2022
|
Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates
- Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months
- Provention Bio Inc (NASDAQ: PRVB) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its.
- 03/28/2022
|
Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript
- Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates
- Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/24/2022
|
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
- RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16 th, 2022 at 10:00am EST.
- 02/10/2022
|
Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
- We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals.
- 02/04/2022
|
Why Provention Bio Stock Is Soaring Today
- The company plans to refile for approval of its experimental type 1 diabetes therapy.
- 01/28/2022
|
5 Top Penny Stocks To Buy Under $5 Right Now
- Penny stocks to buy for under $5. The post 5 Top Penny Stocks To Buy Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/28/2022
|
Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference
- RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at the H.C.
- 01/06/2022
|
Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know
- The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/25/2021
|
Provention Bio (PRVB) Stock: Why The Price Jumped
- The stock price of Provention Bio Inc (NASDAQ: PRVB) increased by 15.06% in the most recent trading session. This is why it happened.
- 11/23/2021
|
Provention Bio Shares Gain On Teplizumab Regulatory Update For Type 1 Diabetes
- The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PK/PD substudy. Related Link: Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops
- 11/22/2021
|
Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?
- Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/09/2021
|
How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%
- The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/09/2021
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2021 Results - Earnings Call Transcript
- Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
- Provention Bio Inc (NASDAQ: PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all five key CVB strains associated with type 1 diabetes (T1D) autoimmunity.
- 10/26/2021
|
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
- RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on Wednesday, September 29, 2021 at 3:20 pm E.T.
- 09/23/2021
|
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
- RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T.
- 09/16/2021
|
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
- RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.
- 09/13/2021
|
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
- This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
- 09/10/2021
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2021 Results - Earnings Call Transcript
- Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Provention Bio: Blood (Glucose) In The Streets
- It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab.
- 07/30/2021
|
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
- RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets.
- 07/29/2021
|
PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of...
- 07/20/2021
|
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 07/20/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 07/19/2021
|
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pr
- 07/19/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 07/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 07/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/18/2021
|
FINAL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - PRVB
- NEW YORK, July 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline. SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 07/16/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - (PRVB)
- New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB).Shareholders who purchased shares of PRVB during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/provention-bio-inc-loss-submission-form/?id=17728&from=5
- 07/16/2021
|
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
- New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
- 07/16/2021
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- 07/16/2021
|
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 07/16/2021
|
Is Provention Bio a Bad News Buy?
- There's a good case this biotech stock is now at least somewhat undervalued.
- 07/16/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - July 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17700&from=5
- 07/15/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- LOS ANGELES, July 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021 , inclusive (the "Class Period"). If you suffered a loss on your Provention investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/provention-bio-inc/.
- 07/15/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - July 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17660&from=5
- 07/14/2021
|
Rosen, Global Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 07/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get...
- 07/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- New York, New York--(Newsfile Corp. - July 13, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or...
- 07/13/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - (PRVB)
- New York, New York--(Newsfile Corp. - July 12, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB).Shareholders who purchased shares of PRVB during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/provention-bio-inc-loss-submission-form/?id=17589&from=5
- 07/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. (NASDAQ: PRVB) ("Provention Bio") between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go...
- 07/12/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, July 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/10/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - July 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17546&from=5
- 07/09/2021
|
Rosen, Global Investor Counsel, Encourages Provention Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - July 9, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 07/09/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 07/09/2021
|
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
- New York, New York--(Newsfile Corp. - July 7, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17477&wire=5
- 07/07/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - July 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17466&from=5
- 07/07/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get...
- 07/06/2021
|
SHAREHOLDER ALERT: Investigation of Provention Bio Announced by Holzer & Holzer, LLC
- Atlanta, Georgia--(Newsfile Corp. - July 6, 2021) - Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) complied with federal securities laws. On July 6, 2021, Provention announced the issuance of a Complete Response Letter ("CRL") by the FDA for the Company's Biologics License Application ("BLA") for the drug Teplizumab. Specifically, the FDA noted that a recent study "failed to show Pharmacokinetic comparability" and notified Provention that...
- 07/06/2021
|
Here's Why Provention Bio Stock Is Diving Today
- The company's latest letter from the FDA wasn't what investors had hoped for.
- 07/06/2021
|
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
- Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.
- 07/06/2021
|
Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops
- The FDA has issued a Complete Response Letter (CRL) to Provention Bio Inc's (NASDAQ: PRVB) teplizumab marketing application seeking approval for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. The FDA stated that a single, low-dose pharmacokinetic/pharmacodynamic (PK/PD) bridging study in healthy volunteers to compare planned commercial products with drug product originating from drug substances manufactured for historical trials had failed to show PK comparability.
- 07/06/2021
|
Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
- RED BANK, N.J., July 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
- 07/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 07/05/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - July 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17410&from=5
- 07/05/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 07/05/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - July 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 07/02/2021
|
ROSEN, A LEADING LAW FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- NEW YORK, July 2, 2021 /PRNewswire/ -- WHY: New York, N.Y., July 2, 2021.
- 07/02/2021
|
Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, July 01, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/01/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/29/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - June 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 06/29/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/29/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or...
- 06/26/2021
|
Rosen, A Leading Law Firm, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - June 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 06/25/2021
|
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
- This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen appeared first on InvestorPlace.
- 06/24/2021
|
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
- New York, New York--(Newsfile Corp. - June 24, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Provention Bio, Inc. (NASDAQ: PRVB) ("Provention Bio") between November 2, 2020 and April 8, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17153&wire=5
- 06/24/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021No obligation or cost to you.Learn more about your recoverable losses in PRVB:https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17143&from=5
- 06/23/2021
|
Provention Bio: PDUFA Ahead, But Uncertainties Abound
- The Advisory Committee voted 10-7 favoring an approval recommendation for teplizumab.
- 06/23/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 23, 2021) - To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17125&wire=5or contact Joseph E. Levi, Esq. either via...
- 06/23/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
- LOS ANGELES, June 23, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021 , inclusive (the "Class Period").
- 06/23/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/22/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021Learn more about your recoverable losses in PRVB:
- 06/21/2021
|
ROSEN, A TOP RANKED FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - June 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 06/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/21/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- BENSALEM, Pa. , June 21, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 06/21/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRVB
- NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline. SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/16/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/15/2021
|
PRVB Investor Notice: Rosen, Leading Trial Attorneys, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRVB
- New York, New York--(Newsfile Corp. - June 15, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out...
- 06/15/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- LOS ANGELES, June 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB ) securities between November 2, 2020 and April 8, 2021 , inclusive (the "Class Period"). If you suffered a loss on your Provention investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/provention-bio-inc/.
- 06/15/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 06/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/11/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, June 11, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/11/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
- NEW YORK, June 11, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/11/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 10, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/10/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/09/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - June 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 06/08/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/08/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- LOS ANGELES--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). If you suffered a loss on your Provention investments or would like to inquire about potentially pur
- 06/04/2021
|
PRVB Shareholder Update: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- New York, New York--(Newsfile Corp. - June 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...
- 06/04/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/03/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline - PRVB
- NEW YORK, June 2, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline. SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/02/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). Investors suffering losses on their Provention investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their
- 06/02/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/02/2021
|
Provention Bio Announces the Grant of Inducement Awards
- RED BANK, N.J., June 2, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two new employees to purchase an aggregate of 40,000 shares of common stock.
- 06/02/2021
|
SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders
- SAN DIEGO & RED BANK, N.J.--(BUSINESS WIRE)---- $PRVB #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, against the Company and certain of its officers for remedies under the Securities Exchange Act of 1934. Provention is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapeutics and solu
- 06/01/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 06/01/2021
|
Provention Bio to Present at the Jefferies Virtual Healthcare Conference
- RED BANK, N.J., June 1, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 AM E.T.
- 06/01/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 31, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 05/31/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - May 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 05/30/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2021. SO WHAT: If you purchased Provention Bio securities during the Class Per
- 05/30/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - (PRVB)
- New York, New York--(Newsfile Corp. - May 28, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB).Shareholders who purchased shares of PRVB during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:
- 05/28/2021
|
Why Provention Bio Stock Crashed Today
- An FDA advisory committee vote was a lot closer than anticipated.
- 05/28/2021
|
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
- New York, New York--(Newsfile Corp. - May 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=16328&wire=5
- 05/28/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). Provention investors have until July 20, 2021 to file a lead plaintiff motion. If you suffered a loss on your Pro
- 05/28/2021
|
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleging that the Company violated federal securities laws.Class Period: November 2, 2020 and April 8, 2021Lead Plaintiff Deadline: July 20, 2021Learn more about your recoverable losses in PRVB:
- 05/28/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 05/28/2021
|
FDA Advisory Committee Votes In Favor Of Approval Of Provention Bio's Diabetes Med
- The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of recommending approval of Provention Bio Inc's (NASDAQ: PRVB) teplizumab to delay the development of type 1 diabetes in high-risk children and adults, with most committee members expressing some concerns about trial size and safety. What Happened: In briefing documents released before the meeting, the FDA noted that the study, TN-10, was “relatively small,” with only 44 patients exposed to teplizumab; however, more than 750 patients with new-onset type 1 diabetes were exposed to teplizumab in other controlled clinical studies included in a meta-analysis.
- 05/28/2021
|
FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)
- RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 10 yes and 7 no on the question, "Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?
- 05/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - May 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 05/27/2021
|
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - PRVB
- NEW YORK, May 27, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 05/27/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
- 05/27/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...
- 05/27/2021
|
Provention Bio Stock Trading Halted Today
- RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Nasdaq has halted trading of the Company's common stock.
- 05/27/2021
|
PRVB Stock Price: 26.82% Increase Explanation
- The stock price of Provention Bio, Inc., (Nasdaq: PRVB) increased by 26.82% yesterday. This is why it happened.
- 05/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
- New York, New York--(Newsfile Corp. - May 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...
- 05/25/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) investors concerning the Company's possible violations of federal securities laws. In November 2020, Provention completed the rolling submission of a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for teplizumab for the delay or prevention of clinical T1D in at-risk individuals (the "tep
- 05/25/2021
|
Why Provention Bio Stock Is Trading Higher Today?
- The FDA published Provention Bio Inc's (NASDAQ: PRVB) teplizumab-related briefing documents ahead of an Advisory Committee meeting scheduled for May 27 (Thursday). The agency sounded a relatively positive tone on safety and efficacy after identifying deficiencies that preclude discussion of labeling and post-marketing requirements.
- 05/25/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $PRVB #PRVB--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc.
- 05/25/2021
|
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2021. SO WHAT: If you purchased Provention Bio securities during the Class Per
- 05/25/2021
|
PRVB Stock Price: Over 20% Increase Explanation
- The stock price of Provention Bio Inc (NASDAQ: PRVB) increased by over 20% during intraday trading this morning. This is why it happened.
- 05/25/2021
|
PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, May 25, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/prvb.
- 05/25/2021
|
Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
- RED BANK, N.J., May 25, 2021 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the U.S. Food and Drug Administration (FDA) posted briefing documents for the May 27, 2021 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting to review the Biologics License Application (BLA) for teplizumab, Provention Bio's investigational drug candidate for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
- 05/25/2021
|
Implied Volatility Surging for Provention Bio (PRVB) Stock Options
- Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
- 05/25/2021
|
PROVENTION ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Provention Bio, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, both dates inclusive (the “Class Period”). Investors have until July 20, 2021 to apply to the Court to be appointed as lead plaintiff in
- 05/24/2021
|
Notice of Lead Plaintiff Deadline for Shareholders in the Provention Bio, Inc. Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)-- #PRVBstock--The suit alleges defendants issued false statements re: Provention Bio business and prospects, resulting in its stock trading at inflated prices.
- 05/21/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action Against Provention Bio, Inc. and Certain Officers - PRVB
- NEW YORK, May 21, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 05/21/2021
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2021 Results - Earnings Call Transcript
- Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2021 Results - Earnings Call Transcript
- 05/08/2021
|
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
- RED BANK, N.J., May 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021.
- 05/06/2021
|
Provention Bio Announces the Grant of Inducement Awards
- RED BANK, N.J., May 3, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 22 new employees to purchase an aggregate of 423,800 shares of common stock.
- 05/03/2021
|
Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021
- RED BANK, N.J., April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets.
- 04/29/2021
|
Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
- RED BANK, N.J., April 27, 2021 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the Company took part in an informal meeting with the U.S. Food and Drug Administration (FDA) on April 23, 2021, in connection with the FDA's ongoing review of the teplizumab Biologic License Application (BLA) for the delay or prevention of clinical type 1 diabetes (T1D).
- 04/27/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Provention Bio, Inc. - PRVB
- New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Provention and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 04/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Provention Bio, Inc. - PRVB
- NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investors are advised to contact Robert S.
- 04/19/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Provention Bio, Inc. - PRVB
- NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investors are advised to contact Robert S.
- 04/13/2021
|
Are Options Traders Betting on a Big Move in Provention Bio (PRVB) Stock?
- Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
- 04/12/2021
|
Provention Bio: Oversold Territory, An Attractive Buying Opportunity
- Provention Bio is oversold, and the stock is trading at an attractive price level. I expect a sharp rebound shortly. The key question is "when" will Teplizumab be approved, not whether Teplizumab will be approved or not.
- 04/09/2021
|
What's Going On With CELC Stock And PRVB Stock Today?
- Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies.
- 04/09/2021
|
Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes
- Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. Notably, the FDA expressed concerns over teplizumab pharmacokinetics data and comparability when Lilly first put teplizumab into clinical trials.
- 04/09/2021
|
Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
- RED BANK, N.J., April 8, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company's Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.
- 04/08/2021
|
Moving Average Crossover Alert: Provention Bio (PRVB)
- Provention Bio (PRVB) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 03/26/2021
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2020 Results - Earnings Call Transcript
- Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
- Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
- 02/21/2021
|
Provention Bio Announces China Deal For Autoimmune Program
- Provention Bio Inc (NASDAQ: PRVB) is making its way into China with a new deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, in China, Hong Kong, Macau, and Taiwan. Provention will retain all rights to PRV-3279 in the rest of the world.
- 02/18/2021
|
Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
- RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its...
- 01/13/2021
|
Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?
- Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
- 01/12/2021
|
Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
- Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in what could be the first of several indicated populations.
- 01/07/2021
|
Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
- RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright...
- 01/06/2021
|
Provention Bio to Present at the Stifel Virtual Healthcare Conference
- RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18,...
- 11/11/2020
|
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
- Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Provention: An Undercovered Healthcare Stock You Should Know About
- Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA submission is complete.
- 11/03/2020
|
Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
- RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and...
- 11/02/2020
|
Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
- RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In...
- 10/29/2020
|
